Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/10/2023 | $7.00 → $10.00 | Market Perform → Outperform | SVB Securities |
3/2/2022 | $30.00 → $15.00 | Buy | Benchmark |
2/28/2022 | $23.00 → $11.00 | Market Perform | SVB Leerink |
2/1/2022 | $24.00 → $11.00 | Outperform → Neutral | Robert W. Baird |
2/1/2022 | $24.00 → $11.00 | Outperform → Neutral | Baird |
12/2/2021 | $13.00 | Hold | Jefferies |
11/8/2021 | $70.00 → $23.00 | Outperform | RBC Capital |
11/8/2021 | $40.00 → $23.00 | Market Perform | SVB Leerink |
NEW YORK, Aug. 12, 2023 (GLOBE NEWSWIRE) -- Veritiv Corporation (NYSE:VRTV) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of VRTV to an affiliate of Clayton, Dubilier & Rice, LCC for $170.00 per share in cash for each share of VRTV common stock owned. If you are a VRTV investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Fiesta Restaurant Group, Inc. (NASDAQ:FRGI) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary dutie
Continued Strong Organic Revenue Growth of 24% Second Quarter Adjusted EBITDA of $6.3 Million Increased More Than 3x Compared to Second Quarter 2022 MOORESTOWN, N.J., Aug. 7, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, today reported financial results for the second quarter ended June 30, 2023. Highlights from the second quarter ended June 30, 2023 include: Second quarter revenue from continuing operations of $90.0 million
$10.50 Per Share All-Cash Transaction Represents a Significant Premium for Tabula Rasa Stockholders Combination of Two Highly Complementary Companies to Benefit Patients, Providers and Payers with First of its Kind Risk Management Platform in Pharmacy Care Expands the Reach of Tabula Rasa's MedWise Technology Platform to Multiple Provider and Payer Markets MOORESTOWN, N.J., Aug. 7, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® ("TRHC," "Tabula Rasa" or the "Company") (NASDAQ:TRHC), a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, today announced it has entered into a definitive agreement (the "Agreement") to be acquired by Nauti
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
SVB Securities upgraded Tabula Rasa HealthCare from Market Perform to Outperform and set a new price target of $10.00 from $7.00 previously
Benchmark reiterated coverage of Tabula Rasa HealthCare with a rating of Buy and set a new price target of $15.00 from $30.00 previously
SVB Leerink reiterated coverage of Tabula Rasa HealthCare with a rating of Market Perform and set a new price target of $11.00 from $23.00 previously